Results for 'CMO ADC'
Content Type: All
Sorted by: Relevance
Showing 1 to 10 results of 424
News
Piramal Aiming High in ADC Market
Company targets becoming the global market leader in development & manufacturing of ADCs.
News
Scottish CMO to Unveil Facility Expansion at CPhI
CMO will increase floor space at its Scotland-based site by 20%.
News
CRT and ADC Therapeutics Join Forces on ADCs
Both Companies sign agreements to develop ADCs using CRT antibodies and peptides, and ADCT’s ‘warhead’ and linker chemistries.
News
Novasep Invests €10M to Reinforce its Bioconjugation Services
Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.
News
Bruker Announces Acquisition of CMO InVivo Biotech
Bruker Announces Acquisition of CMO InVivo Biotech to Expand Molecular Biology, Microbiology and Pathology Consumables and Assay Business
Whitepaper
ADC Therapeutics Drives Productivity with Labguru
ADC Therapeutics develops proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers.
News
NBE Announces Validation of its SMAC-Technology for ADC Development
Successful validation of SMAC™-Technology at World ADC summit 2014 in Frankfurt, Germany.
News
Carbogen Amcis AG Makes Capital Investments in ADC
New ADC capabilities benefit oncology innovators.
News
ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics
Adds an additional proprietary ADC development program in oncology.
News
Seattle Genetics and Genmab Enter into New ADC Collaboration
New ADC program will target AXL expressed on multiple tumor types.
Advertisement
